Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Year-End Push To Meet FDAAA Puts 14 Advisory Committee Meetings On Tap

This article was originally published in The Tan Sheet

Executive Summary

The Center for Drug Evaluation and Research will hold more than twice the typical number of advisory committee meetings in November and December this year - capping off a significant overall increase in panels convened in 2008

You may also be interested in...



Traditional Chinese Medicine Grows As Target For New Drug Opportunities

Nestle Health and Hutchison China MediTech’s JV has an ongoing phase III trial hoping to validate traditional Chinese medicine for Western health care systems. Reports of TCM contamination at China-based firms represent a market-incursion opportunity for Western firms with established supply chains.

Traditional Chinese Medicine Grows As Target For New Drug Opportunities

Nestle Health and Hutchison China MediTech’s JV has an ongoing phase III trial hoping to validate traditional Chinese medicine for Western health care systems. Reports of TCM contamination at China-based firms represent a market-incursion opportunity for Western firms with established supply chains.

FDA Using More Temporary Advisory Committee Members To Fill Vacancies

FDA advisory committees are increasingly relying on temporary members to fill their ranks - a trend that could result in less predictability for drug sponsors at a make-or-break review meeting

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel